Table 4.
Adverse drug reactions types associated with adalimumab, infliximab, and vedolizumab.
| Adalimumab (n = 54) | Infliximab (n = 75) | Vedolizumab (n = 17) | |
|---|---|---|---|
| Reaction type (n (%))a | |||
| Skinb | 9 (16.7) | 16 (21.3) | 6 (35.3) |
| Neurologicalc | 11 (20.4) | 12 (16.0) | 2 (11.8) |
| Musculoskeletald | 5 (9.3) | 15 (20.0) | 3 (17.6) |
| Gastrointestinale | 7 (13.0) | 4 (5.3) | 2 (11.8) |
| Cardiovascularf | 3 (5.6) | 4 (5.3) | – |
| Site injectiong | 6 (11.1) | – | – |
| Infectionsh | 1 (1.9) | 3 (4.0) | – |
| Respiratoryi | 1 (1.9) | 3 (4.0) | – |
| Otherj | 11 (20.4) | 18 (24.0) | 4 (23.5) |
Proportion calculated on total available data.
Includes urticarial, dermatitis, psoriasis, acne, eczema, erythema, pruritus, dryness, and brown spots.
Includes vertigo, dizziness, headaches, confusion, hypoesthesia, dysarthria, memory loss, and absences.
Includes arthralgia and myalgia.
Includes nausea, vomiting, anorexia, gastroesophageal reflux, and dyspepsia.
Includes cardiopathy, peripheral edema, increased blood pressure, and palpitations.
Includes redness, swelling, itching, heat, and pain at site injection.
Includes cellulitis and recurrent infections.
Includes exacerbated asthma and dyspnea.
Includes asthenia, alopecia, gum edema, night sweats, hot flashes, shivers, dysphagia, and weight loss.